(lp0
S'Supernus Pharmaceuticals: The Investment Case Improves Seeking Alpha - Dec 15, 2016 Tier 2 biotech concern Supernus Pharmaceuticals received some good news regarding key patent litigation this week. This the latest piece of positive news for ... This removes an overhang from the company and the stock. Oxtellar XR is the lesser of two ...'
p1
aS'Supernus Pharmaceuticals Offers A Rare Opportunity For Investors Seeking Alpha - Jan 5, 2017 Supernus Pharmaceuticals  is a rarity among the thousands of publicly-traded biotechnology firms; it has approved products, revenue and earnings.'
p2
aS'Supernus Pharmaceuticals Inc.  Soars 5.38% on March 02 Equities.com - Mar 2, 2017 Supernus Pharmaceuticals Inc.  had a good day on the market for Thursday March 02 as shares jumped 5.38% to close at $27.40.'
p3
aS'Cadila inks pact with Supernus Pharma to settle patent issue Moneycontrol.com - Mar 7, 2017 Cadila Healthcare, along with subsidiary Zydus Pharmaceuticals  Inc, have finalised an agreement with Supernus Pharmaceuticals Inc to settle all outstanding patent litigation related to Trokendi XR  extended-release capsules, Cadila&nbsp;...Supernus Pharma Tanks on Settlement of Two Patent Disputes  - InvestopediaAnalyst Activity  Cantor Fitzgerald Reiterates Buy on Supernus ... - Market Exclusive'
p4
aS'Supernus Is Moving In The Right Direction Seeking Alpha - Jan 26, 2017 Supernus Is Moving In The Right Direction ... The marketed product portfolio continues to grow at a healthy pace and the company is on its way to becoming significantly profitable in 2017 considering the growing revenues and solid operating leverage.'
p5
aS"Supernus Pharmaceuticals'  CEO Jack Khattar on Q3 2016 Results ... Seeking Alpha - Nov 18, 2016 Good morning everyone, and thank you for joining us today for Supernus Pharmaceuticals' third quarter 2016 business update conference call."
p6
aS'Is Supernus Accurately Evaluating The Market Opportunity? Seeking Alpha - Nov 28, 2016 Supernus Pharmaceuticals  was supposed to release its results for the three months ended September 30, 2016, in late November.'
p7
aS'Supernus: Reasonable Valuation And Strong Future Growth Seeking Alpha - Oct 5, 2016 Supernus Pharmaceuticals  has already proven itself as a profitable generic drug maker with positive cash flow.'
p8
aS'Jefferies Group LLC Boosts Supernus Pharmaceuticals Inc  Price Target to ... BNB Daily  - Mar 13, 2017 Supernus Pharmaceuticals Inc logo Supernus Pharmaceuticals Inc  had its price objective lifted by Jefferies Group LLC from $33.00 to $35.00 in a report issued on Wednesday morning.Supernus Pharmaceuticals Inc.  Moves Lower on Volume Spike for March 10 - Equities.comSupernus Pharmaceuticals Inc Realized Volatility Hits An Extraordinary High - CML News'
p9
aS'Supernus Announces Issuance of Eighth US Patent Protecting Trokendi XR GlobeNewswire  - Feb 8, 2017 ROCKVILLE, Md., Feb. 08, 2017  -- Supernus Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases,&nbsp;...'
p10
a.